Urogen Pharma (NASDAQ:URGN) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, March 15th. Analysts expect Urogen Pharma to post earnings of ($0.65) per share for the quarter.
Shares of Urogen Pharma (URGN) opened at $56.94 on Tuesday. Urogen Pharma has a 1 year low of $13.01 and a 1 year high of $58.66.
A number of equities research analysts recently issued reports on the stock. Oppenheimer set a $51.00 target price on shares of Urogen Pharma and gave the stock an “outperform” rating in a research report on Tuesday, November 14th. CIBC reiterated an “outperform” rating and set a $51.00 target price (up previously from $32.00) on shares of Urogen Pharma in a research report on Wednesday, November 15th. Raymond James Financial cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 15th. UBS Group cut shares of Urogen Pharma from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 15th. Finally, Cowen restated a “buy” rating on shares of Urogen Pharma in a research report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $39.00.
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.